A 26% relative hazard reduction in recurrent ischemic stroke was observed (HR 0.74), with primary efficacy assessed as time to first ischemic stroke. OCEANIC-STROKE trial data show asundexian cuts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results